Cessatech A/S (NGM:CESSA)

Sweden · Delayed Price · Currency is SEK · Price in DKK

17.02

-0.78 (-4.38%)

At close: Mar 2, 2026

43.63% (1Y)

Market Cap	471.86M
Revenue (ttm)	8.29M
Net Income (ttm)	-15.80M
Shares Out	18.58M
EPS (ttm)	-0.87
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	51,953
Average Volume	38,095
Open	17.80
Previous Close	17.80
Day's Range	15.20 - 17.80
52-Week Range	6.00 - 26.00
Beta	0.76
RSI	41.06
Earnings Date	Feb 27, 2026

About Cessatech

Cessatech A/S, a pharmaceutical company, develops and commercializes medicines for the treatment of pediatric acute pain in Denmark. The company’s lead product is CT001, an analgesic nasal spray for the treatment of acute and planned painful procedures in children. It also develops CT002, a nasal spray for sedative procedures for children from 0-17 years of age; and CT003, a local anesthetic gel. The company has a collaboration and license agreement with Ventis Pharma Corporation to develop and formulate pain management therapies. Cessatech A/S... [Read more]

Industry Pharmaceutical Preparations

Founded 2020

Employees 4

Stock Exchange Nordic Growth Market

Ticker Symbol CESSA

Full Company Profile

Financial Performance

In 2025, Cessatech's revenue was 5.72 million, an increase of 130.01% compared to the previous year's 2.49 million. Losses were -10.90 million, -25.67% less than in 2024.

Financial numbers in DKK Financial Statements

News

There is no news available yet.